Strategic partnerships Nanoform collaborates with global pharma and biotech partners to develop nanoparticle-based formulations, presenting opportunities to position as a key supplier for co-development programs with Takeda and other potential collaborators in rare/solubility-challenged therapies.

Financing momentum Recent €5M R&D loans and grants underscore strong financial support for nanoformulation programs, suggesting buyers may leverage external funding channels and be receptive to joint funding opportunities for early-stage and clinical-stage initiatives.

Geographic expansion Facility expansions to Helsinki and northern Europe indicate capacity growth and proximity to European clients, enabling faster timelines for GMP manufacturing of nanoformed APIs and potential regional pilot programs.

Technology edge Proprietary CESS technology and focus on improving solubility and bioavailability align with demand for solvent-reduction and enhanced delivery platforms, offering a differentiator for discussions with partners seeking improved oral and injectable formulations.

Clinical momentum Active collaboration with Takeda and ongoing proof-of-concept studies point to a track record of clinically relevant outcomes, presenting a strong case for approaching other pharmaceutical companies pursuing late-stage solubility and delivery improvements.